Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. The company owns several molecules with interesting activity and safety profiles. Dybly research is based on a sequence of hypothesis-driven small molecule drug design with validation by empirical data.

Our scientific results demonstrate activity in the following pathways:

• BET-Bromodomain (inhibition)

• Apo A1 (upregulation)

• Inflammation (downregulation)

• Fibrosis (downregulation)

• Blood cancers: MML and AML (suppression of proliferation)

Indications we are interested in:

Fibrotic diseases (lung, liver, heart), Blood cancers, Rheumatoid arthritis and other inflammatory diseases, diseases associated with senescence.

Please contact us to discuss testing these exciting compounds